The agency had pledged to investigate safety concerns regarding the drug two years ago. This new deadline means the evaluation will conclude more than two years after the administration first committed to the review process.
Wednesday, October 21, 2026
Story
FDA Delays Mifepristone Safety Review Until March After 2 Year Pledge
US Politics13 days ago
Medical practitioners are awaiting a new federal safety determination for medications used in abortions. The FDA announced it will not finish its safety review of mifepristone until March, leaving the status of the drug's safety profile unresolved in the interim.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.